You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anaplastic lymphoma kinase positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)

Not yet recruiting
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • (no location specified)
Jul 7, 2023

NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)

Not yet recruiting
  • NSCLC Stage IV
  • ALK Fusion Protein Expression
  • Peptide vaccine
  • (no location specified)
Jul 21, 2023

free Survival and Evaluate Participant Experience for Metastatic

Active, not recruiting
  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung
  • Maynard, Massachusetts
    EmpiraMed, Inc.
Feb 28, 2022

NSCLC Trial in Germany (Brigatinib, Tyrosine kinase inhibitor)

Recruiting
  • NSCLC
  • Berlin, Germany
  • +25 more
Nov 10, 2022

NSCLC Trial in Tianjin (Ensartinib, Placebo)

Recruiting
  • Non-small Cell Lung Cancer
  • Tianjin, China
    TianJin Medical University Cancer Institute & Hospital
Jul 13, 2022

NSCLC Trial in Chang Chun (XZP-3621, Crizotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Chang Chun, Ji Lin, China
    Jilin Province Cancer Hospital
Jan 10, 2022

NSCLC Trial in Shanghai (WX-0593)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, China
    Shanghai Jiao Tong University Chest Hospital
Mar 24, 2023

Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer

Active, not recruiting
  • Non-Small-Cell Lung Carcinoma
  • New York, New York
    Pfizer Inc
Apr 12, 2022

Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

Recruiting
  • Relapsed Plasmablastic Lymphoma
  • +2 more
  • Belantamab Mafodotin
  • Boston, Massachusetts
  • +2 more
Sep 20, 2021

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Beijing, Beijing, China
    Department of Respiratory and Critical Care Medicine, Peking Uni
Aug 10, 2022

Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

Active, not recruiting
  • ALK-Positive Anaplastic Large Cell Lymphoma
  • RNAseq
  • Toulouse, France
    IUCT-Oncopole University Hospital
Jul 3, 2023

Alectinib in Anaplastic Lymphoma Kinase-Positive, Locally

Completed
  • Non-Small Cell Lung Cancer
  • Busan, Korea, Republic of
  • +36 more
Nov 17, 2022

ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)

Active, not recruiting
Has Results
  • ALK-positive Advanced NSCLC
  • Orange, California
  • +79 more
Nov 15, 2022

NSCLC ALK-positive, NSCLC c-Met Dependent, NSCLC ROS Marker Positive Trial in Worldwide (PF-02341066, Rifampin, Itraconazole)

Completed
Has Results
  • Non-Small Cell Lung Cancer ALK-positive
  • +4 more
  • Orange, California
  • +28 more
Feb 15, 2022

Carcinoma, Non-Small-Cell Lung Trial in Worldwide (Lorlatinib)

Recruiting
  • Carcinoma
  • Non-Small-Cell Lung
  • Orange, California
  • +31 more
Dec 6, 2022

NSCLC Trial (Brigatinib)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Feb 18, 2021

Tumors Malignant Trial in Worldwide (Crizotinib)

Active, not recruiting
  • Neoplasms Malignant
  • Fayetteville, Arkansas
  • +20 more
Oct 5, 2021

ALK or ROS1-positive NSCLC Trial in China (Crizotinib)

Active, not recruiting
  • ALK or ROS1-positive NSCLC
  • Fuzhou, Fujian, China
  • +9 more
Aug 30, 2022

Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors

Withdrawn
  • Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma
  • +2 more
  • (no location specified)
Mar 2, 2020

Tumors, Colorectal Tumors, Melanoma Trial in United States (Alectinib)

Terminated
  • Neoplasms
  • +27 more
  • Culver City, California
  • +28 more
Jul 25, 2022

NSCLC Trial in Worldwide (Alectinib, Crizotinib)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Phoenix, Arizona
  • +125 more
Dec 2, 2022

Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

Recruiting
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Paris, France
  • +1 more
Sep 27, 2022

Non Small Cell Lung Cancer Trial in Italy (Alectinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Meldola, Forlì-Cesena, Italy
  • +19 more
Aug 16, 2021

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

NSCLC Trial in Beijing (WX-0593 Tablets, crizotinib)

Unknown status
  • Non-small Cell Lung Cancer
  • Beijing, Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Nov 11, 2020